Annuncio • Aug 21
Enzo Biochem, Inc. Files Form 15 Enzo Biochem, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.01 per share. Annuncio • Aug 20
Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P completed the acquisition of Enzo Biochem, Inc. (OTCPK:ENZB). Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million on June 23, 2025. Battery will acquire Enzo for $0.70 per share in cash, representing a total consideration of approximately $37 million. In case of termination of transaction, Battery Ventures L.P will pay a termination fee of $1 million and Enzo will pay a termination fee of $2.5 million.
The special committee of the Enzo Board of Directors (the “Strategic Committee”) to conduct a comprehensive review of value-maximizing alternatives. The transaction has been unanimously approved by the board of directors of Battery and Enzo and is subject to customary closing conditions, including shareholder approval. Subject to the satisfaction of these conditions, the transaction is expected to close in the third quarter of the calendar year. Following the closing of the transaction, Enzo will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges. As of August 19 2025, the transaction was approved by target shareholders.
BroadOak Capital Partners, LLC acted as financial advisor and fairness opinion provider for Enzo Biochem, Inc. Adam W. Finerman of Baker & Hostetler LLP acted as legal advisor for Enzo Biochem, Inc. Alfred Browne and Izzy Lubarsky of Cooley LLP acted as legal advisor for Battery Ventures L.P. Equiniti Trust Company, LLC acted as Transfer agent to Enzo Biochem. Kingsdale Advisors LP acted as a proxy solicitor to Enzo Biochem.
Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P completed the acquisition of Enzo Biochem, Inc. (OTCPK:ENZB) on August 20, 2025. Annuncio • Jun 26
Enzo Biochem to Delist After Merger Completion Enzo Biochem announced that on June 23, following the market close, it entered into an Agreement and Plan of Merger to be acquired by Battery Ventures, a technology-focused investment firm, through its newly formed entity Bethpage Parent. Under the terms of the merger agreement, Battery will acquire Enzo for 70c per share in cash, representing a total consideration of approximately $37 million. Following the closing of the transaction, the company will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges. Annuncio • Jun 25
Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million. Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million on June 23, 2025. Battery will acquire Enzo for $0.70 per share in cash, representing a total consideration of approximately $37 million. In case of termination of transaction, Battery Ventures L.P will pay a termination fee of $1 million and Enzo will pay a termination fee of $2.5 million.
The special committee of the Enzo Board of Directors (the “Strategic Committee”) to conduct a comprehensive review of value-maximizing alternatives. The transaction has been unanimously approved by the board of directors of Battery and Enzo and is subject to customary closing conditions, including shareholder approval. Subject to the satisfaction of these conditions, the transaction is expected to close in the third quarter of the calendar year. Following the closing of the transaction, Enzo will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges.
BroadOak Capital Partners, LLC acted as financial advisor and fairness opinion provider for Enzo Biochem, Inc. Adam W. Finerman of Baker & Hostetler LLP acted as legal advisor for Enzo Biochem, Inc. Alfred Browne and Izzy Lubarsky of Cooley LLP acted as legal advisor for Battery Ventures L.P. Reported Earnings • Mar 18
Second quarter 2025 earnings released: US$0.024 loss per share (vs US$0.017 loss in 2Q 2024) Second quarter 2025 results: US$0.024 loss per share (further deteriorated from US$0.017 loss in 2Q 2024). Revenue: US$7.33m (down 14% from 2Q 2024). Net loss: US$1.25m (loss widened 45% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Annuncio • Jan 16
Enzo Biochem Receives Non-Compliance Letter from NYSE On January 8, 2025 Enzo Biochem, Inc. (the Company") received a letter from the New York Stock Exchange (the NYSE") notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Manual because as of January 7, 2025, the Company's 30 trading-day average market capitalization was less than $50 million and its last reported stockholder's equity as of October 31, 2024 was less than $50 million and (ii) Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's Common Stock (the Common Stock") was less than $1.00 over a consecutive 30 trading-day period. The Company has a period of 18 months to cure the market capitalization and stockholder's equity deficiencies and a period of six months to cure the average closing stock price deficiency. The notice does not result in the immediate delisting of the Common Stock from the NYSE. With regards to the average closing stock price deficiency, the Company can regain compliance at any time within the six-month period following receipt of the NYSE's non-compliance notice if, on the last trading day of any calendar month during the cure period, the Company has (i) a closing share price of at least $1.00 and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. Under the NYSE's listing rules, the price condition will be deemed cured if the price promptly exceeds $1.00 per share and the price remains above that level for at least the following 30 consecutive trading days. The Company will notify the NYSE by January 23, 2025, that it intends to submit a plan by February 21, 2025, to cure the market capitalization, stockholder's equity and average closing stock price deficiencies and to return to compliance with the NYSE's continued listing standards. The Company intends to consider all available alternatives to cure the deficiencies identified by the NYSE. The Common Stock will continue to be listed and trade on the NYSE, subject to the Company's ongoing compliance with the NYSE's other continued listing standards. Reported Earnings • Dec 17
First quarter 2025 earnings released: US$0.059 loss per share (vs US$0.11 loss in 1Q 2024) First quarter 2025 results: US$0.059 loss per share (improved from US$0.11 loss in 1Q 2024). Revenue: US$6.21m (down 20% from 1Q 2024). Net loss: US$3.07m (loss narrowed 46% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings. Board Change • Dec 01
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Director Brad Radoff is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. New Risk • Nov 01
New minor risk - Dividend sustainability The company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 35% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Short dividend paying track record (less than a year of continuous dividend payments). Shareholders have been diluted in the past year (5.1% increase in shares outstanding). Market cap is less than US$100m (US$60.1m market cap). Reported Earnings • Oct 30
Full year 2024 earnings released: US$0.19 loss per share (vs US$0.51 loss in FY 2023) Full year 2024 results: US$0.19 loss per share (improved from US$0.51 loss in FY 2023). Revenue: US$31.9m (up 2.7% from FY 2023). Net loss: US$9.82m (loss narrowed 61% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings. Annuncio • Oct 30
Enzo Biochem, Inc. Announces Cash Dividend, Payable on December 2, 2024 The Board of Directors of Enzo Biochem, Inc. has declared a cash dividend of $0.10 per share on its common stock, payable on December 2, 2024, to the holders of record as of the close of business on November 15, 2024. Board Change • Sep 20
High number of new and inexperienced directors There are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Brad Radoff is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jun 16
Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.31 loss in 3Q 2023) Third quarter 2024 results: US$0.042 loss per share (improved from US$0.31 loss in 3Q 2023). Revenue: US$8.02m (down 50% from 3Q 2023). Net loss: US$2.13m (loss narrowed 86% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 14
Second quarter 2024 earnings released: US$0.017 loss per share (vs US$0.059 loss in 2Q 2023) Second quarter 2024 results: US$0.017 loss per share (improved from US$0.059 loss in 2Q 2023). Revenue: US$8.55m (up 14% from 2Q 2023). Net loss: US$863.0k (loss narrowed 70% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance. Annuncio • Dec 23
Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024 Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024, at 09:00 US Eastern Standard Time. Annuncio • Nov 01
Enzo Biochem, Inc. announced delayed annual 10-K filing On 10/31/2023, Enzo Biochem, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Annuncio • Oct 31
Enzo Biochem, Inc. Appoints Steven J. Pully to its Board of Directors Enzo Biochem, Inc. announced that Steven J. Pully has been appointed to the Company’s Board of Directors effective October 26, 2023. Mr. Pully will assume the role of Chairperson of the Board, and Chair of the Audit Committee as well. Mr. Pully is currently a partner of Speyside Partners, an investment banking firm that he co-founded in May 2017. He also serves on the boards or in executive positions for various companies, including publicly-traded RumbleOn, Inc., where he serves as the Executive Chairman. Mr. Pully’s board service has spanned multiple industries, including airlines, amusement parks, energy and power, manufacturing, power sports, retail, restaurants, and technology. His board service has included multiple positions as chairman or lead director of the board, and also multiple chairmanships of audit, compensation, nominating and governance, and special committees. Previously, Mr. Pully served as General Counsel and as a Partner of the investment firm, Carlson Capital, L.P. from 2008 to 2014, as Managing Director in the investment banking division of Bank of America and as a Senior Managing Director in the investment banking department of Bear Stearns & Company. Mr. Pully is also an attorney and CPA, he is a Chartered Financial Analyst, and he also holds various FINRA licenses. Board Change • Sep 09
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder & Director Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Annuncio • Sep 07
Enzo Biochem, Inc. Announces CEO Changes Enzo Biochem, Inc. announced that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo’s Chief Operating Officer, Kara Cannon, assuming the role of interim CEO. For more than 45 years, Enzo Biochem has been a leader in innovation and product development to support a diverse range of needs in biomedical research and healthcare. With a comprehensive portfolio of thousands of high-quality products including antibodies, genomic probes, assays, biochemicals, and proteins, Enzo Biochem, Inc.’s Life Science division supports the work of academic research centers and industry partners who are shaping the future of healthcare around the world. The company’s proprietary products and technologies play central roles in all areas of translational research and drug development, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Annuncio • May 10
Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027 Enzo Biochem, Inc. provided earnings guidance for the years 2023, 2024, 2025, 2026 and 2027. For the year 2023, the company expects revenue of $52.0 million and LBIT of $15.8 million. For the year 2024, the company expects revenue of $70.4 million and LBIT of $14.4 million. For the year 2025, the company expects revenue of $80.9 million and LBIT of $11.5 million. For the year 2026, the company expects revenue of $94.4 million and LBIT of $6.8 million. For the year 2027, the company expects revenue of $112.7 million and EBIT of $2.6 million. Reported Earnings • Mar 22
Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.055 loss in 2Q 2022) Second quarter 2023 results: US$0.23 loss per share (further deteriorated from US$0.055 loss in 2Q 2022). Revenue: US$16.3m (down 52% from 2Q 2022). Net loss: US$11.3m (loss widened 326% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 7% per year. Reported Earnings • Dec 13
First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.048 loss in 1Q 2022) First quarter 2023 results: US$0.22 loss per share (further deteriorated from US$0.048 loss in 1Q 2022). Revenue: US$18.3m (down 31% from 1Q 2022). Net loss: US$10.6m (loss widened 359% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings. Recent Insider Transactions • Nov 29
CEO & Director recently bought US$197k worth of stock On the 23rd of November, Hamid Erfanian bought around 100k shares on-market at roughly US$1.97 per share. This transaction amounted to 36% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth US$5.0m. Hamid has been a buyer over the last 12 months, purchasing a net total of US$207k worth in shares. Recent Insider Transactions • Nov 25
Insider recently bought US$5.0m worth of stock On the 18th of November, James Wolf bought around 662k shares on-market at roughly US$7.50 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$8.0m more in shares than they have sold in the last 12 months. Board Change • Nov 16
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder & Director Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Annuncio • Nov 09
Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2023 Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2023. Reported Earnings • Oct 16
Full year 2022 earnings released Full year 2022 results: Net income: (down US$7.88m from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Jul 08
Independent Director recently bought US$264k worth of stock On the 5th of July, Bradley Radoff bought around 120k shares on-market at roughly US$2.20 per share. In the last 3 months, they made an even bigger purchase worth US$276k. Insiders have collectively bought US$7.0m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Jun 18
Independent Director recently bought US$276k worth of stock On the 16th of June, Bradley Radoff bought around 125k shares on-market at roughly US$2.20 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$6.7m more in shares than they have sold in the last 12 months. Reported Earnings • Jun 10
Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.041 profit in 3Q 2021) Third quarter 2022 results: US$0.10 loss per share (down from US$0.041 profit in 3Q 2021). Revenue: US$26.2m (down 20% from 3Q 2021). Net loss: US$4.85m (down 342% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Board Change • Apr 27
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder & Director Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 16
Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2022 results: US$0.055 loss per share (down from US$0.048 profit in 2Q 2021). Revenue: US$34.0m (up 8.2% from 2Q 2021). Net loss: US$2.66m (down 215% from profit in 2Q 2021). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates by 413%. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Board Change • Feb 03
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder, Independent Outside Director & Secretary Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Jan 08
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Co-Founder, Chairman, Chief Scientific Officer & Secretary Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. Lead Independent Director Mary Tagliaferri was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Recent Insider Transactions • Dec 30
Insider recently bought US$2.5m worth of stock On the 21st of December, Bradley Radoff bought around 683k shares on-market at roughly US$3.64 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$6.5m more in shares than they have sold in the last 12 months. Reported Earnings • Dec 17
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2022 results: US$0.048 loss per share (down from US$0.006 profit in 1Q 2021). Revenue: US$26.5m (down 7.5% from 1Q 2021). Net loss: US$2.32m (down US$2.62m from profit in 1Q 2021). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates by 413%. Earnings per share (EPS) missed analyst estimates by 413%. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Oct 24
Insider recently bought US$1.5m worth of stock On the 21st of October, Bradley Radoff bought around 415k shares on-market at roughly US$3.60 per share. In the last 3 months, they made an even bigger purchase worth US$2.5m. Insiders have collectively bought US$4.0m more in shares than they have sold in the last 12 months. Valuation Update With 7 Day Price Move • Oct 20
Investor sentiment deteriorated over the past week After last week's 15% share price decline to US$3.25, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 22x in the Healthcare industry in the US. Total returns to shareholders of 4.8% over the past three years. Reported Earnings • Oct 13
Full year 2021 earnings released: EPS US$0.16 (vs US$0.60 loss in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: US$117.7m (up 55% from FY 2020). Net income: US$7.88m (up US$36.4m from FY 2020). Profit margin: 6.7% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Oct 08
Insider recently bought US$2.5m worth of stock On the 5th of October, Bradley Radoff bought around 721k shares on-market at roughly US$3.42 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$2.6m more in shares than they have sold in the last 12 months. Reported Earnings • Jun 12
Third quarter 2021 earnings released: EPS US$0.041 (vs US$0.21 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$32.8m (up 94% from 3Q 2020). Net income: US$2.01m (up US$11.9m from 3Q 2020). Profit margin: 6.1% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings. Reported Earnings • Mar 17
Second quarter 2021 earnings released: EPS US$0.048 (vs US$0.16 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$31.5m (up 62% from 2Q 2020). Net income: US$2.30m (up US$9.99m from 2Q 2020). Profit margin: 7.3% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Feb 05
New 90-day high: US$3.25 The company is up 66% from its price of US$1.96 on 06 November 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 3.0% over the same period. Is New 90 Day High Low • Jan 05
New 90-day high: US$2.66 The company is up 22% from its price of US$2.18 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 12% over the same period. Reported Earnings • Dec 12
First quarter 2021 earnings released: EPS US$0.006 The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$28.7m (up 42% from 1Q 2020). Net income: US$299.0k (up US$7.95m from 1Q 2020). Profit margin: 1.0% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.